Association between immune-related adverse events and survival in patients with renal cell carcinoma treated with nivolumab plus ipilimumab: immortal time bias-corrected analysis

ConclusionsDeveloping irAEs, particularly multiple irAEs, is associated with favourable survivals in advanced RCC patients treated with nivolumab plus ipilimumab.
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research